CryoPort

CYRX

時価総額 $8.53億

Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Cryoport, Inc., rated BUY, is up 82% YTD, driven by robust cell and gene therapy (CGT) commercialization and pipeline momentum. CYRX returned to adjusted EBITDA profitability in 2Q26, with strong Life Science Services growth and positive operating cash flow of $8 million TTM. Management expects 5 new CGT commercial approvals in 2026, supported by a 15% YoY increase in the Phase 3 trial pipeline to 94 trials.

CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript

CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.

Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.

IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).